Sutro Biopharma Reports Q3 2026 Results, $9.1M Revenue and $31.5M Net Loss

Sutro Biopharma reported third-quarter 2026 revenue of $9.1 million and a net loss of $31.5 million. Operating expenses totaled $31.1 million, down from $58.2 million a year earlier. The company reported $142.2 million in cash, cash equivalents and marketable securities and expects its cash runway…